Citi Upgrades Horizon Pharma (HZNP) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Paramount Skydance to close WBD deal, change ticker to SKYD
BMO Sees Favorable Risk/Reward for Horizon Pharma (HZNP) Ahead of phase 3 Data for Actimmune in FA
November 28, 2016 6:56 AM ESTBMO Capital analyst Gary Nachman sees favorable risk/reward for Horizon Pharma (NASDAQ: HZNP) into Phase 3 data for Actimmune in Friedreich's Ataxia (FA).
Nachman commented, "ased on feedback from ataxia specialists that we include in the note and considering how HZNP... More



